Intellia Therapeutics Inc

For the period ended Dec 31, 2023. Filed Feb 22, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 22, 2024

NTLA$11.17-7.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Amounts in thousands except per share data)
	Year Ended December 31,
	2023	2022	2021
Collaboration revenue (1)	$36,275	$52,121	$33,053
Operating expenses:
Research and development	435,069	419,979	229,807
General and administrative	116,497	90,306	71,096
Total operating expenses	551,566	510,285	300,903
Operating loss	(515,291)	(458,164)	(267,850)
Other income (expense), net:
Interest income	49,832	8,542	1,283
Loss from equity method investment	(15,633)	(11,079)	(1,325)
Change in fair value of contingent consideration	(100)	(13,485)	-
Total other income (expense), net	34,099	(16,022)	(42)
Net loss	$(481,192)	$(474,186)	$(267,892)
Net loss per share, basic and diluted	$(5.42)	$(6.16)	$(3.78)
Weighted average shares outstanding, basic and diluted	88,770	76,972	70,894
Other comprehensive loss:
Unrealized gain (loss) on marketable securities	3,635	(1,637)	(2,126)
Other comprehensive gain (loss) from equity method investment	1,568	(3,192)	(507)
Comprehensive loss	$(475,989)	$(479,015)	$(270,525)
(1) Including the following revenue from related party (see Notes 9 and 16):	$12,832	$21,134	$6,072

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.